Research Article
The Role of Androgen Receptor Expression in the Curative Treatment of Prostate Cancer with Radiotherapy: A Pilot Study
Table 1
Comparison between clinical relapse group and group without relapse during follow-up.
| | Parameter | Clinical relapse () | No relapse during follow-up () |
| | Follow-up (months, median [range]) | | | | After diagnosis | 73 [46–153] | 75 [60–101] | | After primary EBRT | 66 [40–148] | 71 [55–95] | | Age at diagnosis (, median [range]) | 64 [53–74] | 63 [57–76] | | Initial PSA (ng/ml, median [range]) | 30.1 [5.52–126.4] | 13.7 [9.10–75] | | PSA category ( (%)) | | | | PSA <10 ng/ml | 2 (18.2) | 1 (14.3) | | PSA 10–20 ng/ml | 3 (27.3) | 3 (42.9) | | PSA >20 ng/ml | 6 (54.5) | 3 (42.9) | |
N+ (yes (%)) | 7 (63.6) | 4 (57.1) | | Gleason score ( (%)) | | | | ≤6 | 1 (9.1) | — | | 7 | 3 (27.3) | 1 (14.3) | | ≥8 | 7 (63.6) | 5 (71.4) | | Gleason 5 component (yes (%)) | 5 (45.5) | 5 (71.4) | | Clinical T-stage ( (%)) | | | | cT1 | 1 (9.1) | — | | cT2 | 2 (18.2) | 3 (42.9) | | cT3 | 7 (63.6) | 3 (42.9) | | cT4 | 1 (9.1) | 1 (14.3) | | EAU risk classification ( (%)) | | | | Low-risk | — | — | | Intermediate-risk | 1 (9.1) | 1 (14.3) | | High-risk | 2 (18.2) | 1 (14.3) | | Very-high-risk | 8 (72.7) | 5 (71.4) |
|
|
